New agreements underscore QIAGEN’s leadership in bioinformatics
FDA centers and researchers gain access to QIAGEN’s enhanced solutions for applications including microbial and microbiome analysis
Hilden, Germany, and Aarhus, Denmark, February 2, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications.
QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to allow users of QIAGEN’s CLC Genomics Workbench to access and integrate CosmosID’s metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID’s platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN’s microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing.
Metagenomics and microbiome research, which look at the impact of microbial diversity on environment and human health, are growing very rapidly. At the end of 2015, QIAGEN acquired MO BIO Laboratories, Inc., a leader in sample technologies for microbiomes.
Furthermore, QIAGEN announced a contract awarded to its partner Trigent Solutions Inc. that enables streamlined access to QIAGEN’s bioinformatics solutions for centers of the U.S. Food and Drug Administration. Products available to FDA centers include software for infectious disease research and outbreak analysis, such as CLC Genomics Workbench, CLC Microbial Genomics Module, CLC Genome Finishing Module, as well as solutions in human genomics, such as Biomedical Genomics Workbench, Ingenuity® Variant AnalysisTM, and Ingenuity® Pathway AnalysisTM.
The contract expands QIAGEN’s long-standing bioinformatics relationship with the FDA from one Center of Excellence to seven centers, spanning human health and food safety applications. The products and services provided to the FDA also enable uploading and sharing of public health data with U.S. and international institutions via the National Center for Biotechnology Information (NCBI) SRA database of biological sequencing data to combat infectious outbreaks both on national and global levels.
“We are excited about the latest agreements”, said Dr. Laura Furmanski, Senior Vice President and head of QIAGEN’s Bioinformatics Business Area. “They are leveraging the reach and profile of our leading portfolio of bioinformatics solutions that enable a growing number of customers to analyze vast amounts of data from next-generation sequencing – and to arrive at actionable insights.”
To learn more about QIAGEN’s bioinformatics business, please visit http://www.qiagenbioinformatics.com.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).